Treatment

doi:10.1017/CBO9781316091586.019

Section 5 - Treatment

Published online by Cambridge University Press: 05 May 2016

Edited by

Bradford C. Dickerson

Show author details

Bradford C. Dickerson: Affiliation:
Department of Neurology, Massachusetts General Hospital

Book contents

Get access

Information

Type: Chapter
Information: Hodges' Frontotemporal Dementia , pp. 211 - 271

DOI: https://doi.org/10.1017/CBO9781316091586.019 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

James, AB. Activities of daily living and instrumental activities of daily living. In: Crepeau, EB, Cohn, ES, Schell, BAB, editors. Willard Spackman's Occupational Therapy, 11th edn. Baltimore: Lippincott Williams & Wilkins; 2009. p. 538–40.Google Scholar

Lawton, MP, Brody, EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9(3):179–86.10.1093/geront/9.3_Part_1.179CrossRef Google Scholar PubMed

Sonn, U. Longitudinal studies of dependence in daily life activities among elderly persons. Scand J Rehabil Med 1996;34:1–35.Google Scholar PubMed

Mesulam, MM, Wieneke, C, Thompson, C, Rogalski, E, Weintraub, S. Quantitative classification of primary progressive aphasia at early and mild impairment stages. Brain 2012;135:1537–53.10.1093/brain/aws080CrossRef Google Scholar PubMed

Blair, M, Marczinski, CA, Davis-Faroque, N, Kertesz, A. A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc 2007;13:237–45.10.1017/S1355617707070269CrossRef Google Scholar PubMed

Mioshi, E, Hsieh, S, Savage, S, Hornberger, M, Hodges, JR. Clinical staging and disease progression in frontotemporal dementia. Neurology 2010;74:1591–7.10.1212/WNL.0b013e3181e04070CrossRef Google Scholar PubMed

Morris, JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–4.10.1212/WNL.43.11.2412-aCrossRef Google Scholar PubMed

Lima-Silva, TB, Bahia, VS, Carvalho, VA, Guimaraes, HC, Caramelli, P, Balthazar, M, et al. Translation, applicability and cross-cultural adaptation of the Brazilian version of the Frontotemporal Dementia Rating Scale (FTDFRS). Dement Neuropsychol 2013;7:387–96.10.1590/S1980-57642013DN74000006CrossRef Google Scholar PubMed

Knopman, DS, Kramer, JH, Boeve, BF, Caselli, RJ, Graff-Radford, NR, Mendez, MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008;131:2957–68.10.1093/brain/awn234CrossRef Google Scholar PubMed

Hornberger, M, Piguet, O, Kipps, C, Hodges, JR. Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia. Neurology 2008;71(19):1481–8.10.1212/01.wnl.0000334299.72023.c8CrossRef Google Scholar PubMed

Mioshi, E, Kipps, CM, Dawson, K, Mitchell, J, Graham, A, Hodges, JR. Activities of daily living in frontotemporal dementia and Alzheimer disease. Neurology 2007;68:2077–84.10.1212/01.wnl.0000264897.13722.53CrossRef Google Scholar PubMed

Mioshi, E, Hodges, JR. Rate of change of functional abilities in frontotemporal dementia. Dement Geriatr Cogn Disord 2009;28:419–26.CrossRef Google Scholar PubMed

Wicklund, AH, Johnson, N, Rademaker, A, Weitner, BB, Weintraub, S. Profiles of decline in activities of daily living in non-Alzheimer dementia. Alzheimer Dis Assoc Disord 2007;21(1):8–13.10.1097/WAD.0b013e3180324549CrossRef Google Scholar PubMed

Raskovsky, K, Hodges, JR, Knopman, D, Mendez, MF, Kramer, JH, Neuhaus, J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456–77.Google Scholar

Neary, D, Snowden, JS, Gustafson, L, Passant, U, Stuss, D, Black, S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–54.10.1212/WNL.51.6.1546CrossRef Google Scholar PubMed

Lima-Silva, TB, Bahia, VS, Nitrini, R, Yassuda, MS. Functional status in behavioral variant frontotemporal dementia: a systematic review. Biomed Res Int 2013;2013:1–7.10.1155/2013/837120CrossRef Google Scholar PubMed

Garcin, B, Lillo, P, Hornberger, M, Piguet, O, Dawson, K, Nestor, PJ, et al. Determinants of survival in behavioral variant frontotemporal dementia. Neurology 2009;73(20):1656–61.10.1212/WNL.0b013e3181c1dee7CrossRef Google Scholar PubMed

Rascovsky, K, Salmon, DP, Lipton, AM, Leverenz, JB, Decarli, C. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005;65:397–403.10.1212/01.wnl.0000171343.43314.6eCrossRef Google Scholar PubMed

Kipps, CM, Nestor, PJ, Dawson, CE, Mitchell, J, Hodges, JR. Measuring progression in frontotemporal dementia: implications for therapeutic interventions. Neurology 2008;70(22):2046–52.10.1212/01.wnl.0000313366.76973.8aCrossRef Google Scholar PubMed

De Simone, V, Kaplan, L, Patronas, N, Wassermann, EM, Grafman, J. Driving abilities in frontotemporal dementia patients. Dement Geriatr Cogn Disord 2007;23(1):1–7.CrossRef Google Scholar PubMed

Jonah, BA, Thiessen, R, Au-Yeung, E. Sensation seeking, risky driving and behavioral adaptation. Accid Anal Prev 2001;33(5):679–84.10.1016/S0001-4575(00)00085-3CrossRef Google Scholar PubMed

Merrilees, J, Ketelle, R. Advanced practice nursing: meeting the caregiving challenges for families of persons with frontotemporal dementia. Clin Nurse Spec 2010;24(5):245–51.10.1097/NUR.0b013e3181ecdc32CrossRef Google Scholar PubMed

Ghosh, A, Dutt, A. Utilisation behaviour in frontotemporal dementia. J Neurol Neurosurg Psychiatry 2010;81(2):154–6.10.1136/jnnp.2008.160416CrossRef Google Scholar PubMed

Mioshi, E, Kipps, CM, Hodges, JR. Activities of daily living in behavioural variant frontotemporal dementia. Alzheimer Dis Assoc Disord 2009;23(1):70–6.CrossRef Google Scholar

Piguet, O, Hornberger, M, Mioshi, E, Hodges, JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011;10:162–72.10.1016/S1474-4422(10)70299-4CrossRef Google Scholar

Merrilees, J, Dowling, GA, Hubbard, E, Mastick, J, Ketelle, R, Miller, BL. Characterization of apathy in persons with frontotemporal dementia and the impact on family caregivers. Alzheimer Dis Assoc Disord 2013;27(1):62–7.10.1097/WAD.0b013e3182471c54CrossRef Google Scholar PubMed

Rabinovici, GD, Miller, BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010;24(5):375–98.10.2165/11533100-000000000-00000CrossRef Google Scholar PubMed

Litvan, I. Therapy and management of frontal lobe dementia patients. Neurology 2001;56(Suppl 4):S41–5.10.1212/WNL.56.suppl_4.S41CrossRef Google Scholar PubMed

Piguet, O. Eating disturbance in behavioural-variant frontotemporal dementia. J Mol Neurosci 2011;45(3):589–93.10.1007/s12031-011-9547-xCrossRef Google Scholar PubMed

Farmer, J, Grossman, M. Frontotemporal dementia: an overview. Alzheimers Care Q 2005;6(3):225–32.Google Scholar

Le Rhun, E, Richard, F, Pasquier, F. Natural history of primary progressive aphasia. Neurology 2005;65(6):887–91.10.1212/01.wnl.0000175982.57472.84CrossRef Google Scholar PubMed

Bier, N, Macoir, J, Joubert, S, Bottari, C, Chayer, C, Pigot, H, et al. Cooking “Shrimp a la Creole”: a pilot study of an ecological rehabilitation in semantic dementia. Neuropsychol Rehabil 2011;21(4):455–83.10.1080/09602011.2011.580614CrossRef Google Scholar PubMed

Miller, BL, Darby, AL, Swartz, JR, Yener, GG, Mena, I. Dietary changes, compulsions and sexual behavior in frontotemporal dementia. Dementia 1995;6:195–9.Google Scholar

Kashibayashi, T, Ikeda, M, Komori, K, Shinagawa, S, Shimizu, H, Toyota, Y, et al. Transition of distinctive symptoms of semantic dementia during longitudinal clinical observation. Dement Geriatr Cogn Disord 2010;29(3):224–32.10.1159/000269972CrossRef Google Scholar PubMed

Mesulam, MM. Primary progressive aphasia: a language-based dementia. N Engl J Med 2003;349(16):1535–42.10.1056/NEJMra022435CrossRef Google Scholar PubMed

Snowden, JS, Bathgate, D, Varma, A, Blackshaw, A, Gibbons, ZC, Neary, D. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 2001;70:323–32.10.1136/jnnp.70.3.323CrossRef Google Scholar PubMed

Green, HAC, Patterson, K. Jigsaws-a preserved ability in semantic dementia. Neuropsychologia 2009;47(2):569–76.CrossRef Google Scholar PubMed

Seeley, WW, Bauer, AM, Miller, BL, Gorno-Tempini, ML, Kramer, JH, Weiner, M, et al. The natural history of temporal variant frontotemporal dementia. Neurology 2005;64(8):1384–90.10.1212/01.WNL.0000158425.46019.5CCrossRef Google Scholar PubMed

Jang, J, Cushing, N, Clemson, L, Hodges, JR, Mioshi, E. Activities of daily living in progressive non-fluent aphasia, logopenic progressive aphasia and Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:354–60.10.1159/000339670CrossRef Google Scholar PubMed

Cushing, N, Jang, J, O'Connor, CM, Burrell, JR, Clemson, L, Hodges, JR, et al. Disability in atypical parkinsonian syndromes is more dependent on memory dysfunction than motor symptoms. Parkinsonism Relat Disord 2013;19(4):436–40.10.1016/j.parkreldis.2013.01.002CrossRef Google Scholar PubMed

Gorno-Tempini, ML, Hillis, A., Weintraub, S, Kertesz, A, Mendez, M, Cappa, SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006–14.10.1212/WNL.0b013e31821103e6CrossRef Google Scholar PubMed

Kertesz, A, Martinez-Lage, P, Davidson, W, Munoz, DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000;55(9):1368–75.10.1212/WNL.55.9.1368CrossRef Google Scholar PubMed

Gorno-Tempini, ML, Dronkers, NF, Rankin, KP, Ogar, JM, Phengrasamy, L, Rosen, HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55(3):335–46.10.1002/ana.10825CrossRef Google Scholar PubMed

Leyton, CE, Villemagne, VL, Savage, S, Pike, KE, Ballard, KJ, Piguet, O, et al. Subtypes of progressive aphasia: application of the international concensus criteria and validation using B-amyloid imaging. Brain 2011;134(10):3030–43.CrossRef Google Scholar

Mesulam, M, Wicklund, A, Johnson, N, Rogalski, E, Leger, GC, Rademaker, A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008;63(6):709–19.Google Scholar PubMed

Rabinovici, GD, Jagust, WJ, Furst, AJ, Ogar, JM, Racine, CA, Mormino, EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008;64(4):388–401.CrossRef Google Scholar PubMed

Rohrer, JD, Ridgway, GR, Crutch, SJ, Hailstone, J, Goll, JC, Clarkson, MJ, et al. Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage 2010;49(1):984–93.10.1016/j.neuroimage.2009.08.002CrossRef Google Scholar PubMed

Leyton, CE, Hsieh, S, Mioshi, E, Hodges, JR. Cognitive decline in logopenic aphasia: more than losing words. Neurology 2013;80(10):897–903.10.1212/WNL.0b013e318285c15bCrossRef Google Scholar PubMed

Kertesz, A, McMonagle, P, Blair, M, Davidson, W, Munoz, DG. The evolution and pathology of frontotemporal dementia. Brain 2005;128(9):1996–2005.10.1093/brain/awh598CrossRef Google Scholar PubMed

Mathuranath, P, Xuereb, J, Bak, T, Hodges, J. Corticobasal ganglionic degeneration and/or frontotemporal dementia? A report of two overlap cases and review of literature. J Neurol Neurosurg Psychiatry 2000;68(3):304–12.10.1136/jnnp.68.3.304CrossRef Google Scholar PubMed

Mimura, M, White, RF, Albert, ML. Corticobasal degeneration: neuropsychological and clinical correlates. J Neuropsychiatry Clin Neurosci 1997;9(1):94–8.Google Scholar PubMed

Murray, R, Neumann, M, Forman, MS, Farmer, J, Massimo, L, Rice, A, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007;68(16):1274–83.10.1212/01.wnl.0000259519.78480.c3CrossRef Google Scholar PubMed

Mochizuki, A, Ueda, Y, Komatsuzaki, K, Tsuchiya, K, Arai, T, Shoji, S. Progressive supranuclear palsy presenting with primary progressive aphasia – clinicopathological report of an autopsy case. Acta Neuropathol 2003;105(6):610–14.CrossRef Google Scholar PubMed

Diehl-Schmid, J, Bornschein, S, Pohl, C, Forstl, H, Kurz, A, Jahn, T. Cognitive decline in the behavioural variant of frontotemporal dementia. Int Psychogeriatr 2011;23(2):230–7.10.1017/S104161021000164XCrossRef Google Scholar

Josephs, KA, Whitwell, JL, Weigand, SD, Senjem, ML, Boeve, BF, Knopman, DS, et al. Predicting functional decline in behavioural variant frontotemporal dementia. Brain 2011;134(Pt 2):432–48.CrossRef Google Scholar PubMed

Bouwens, SFM, van Heugten, CM, Verhey, FRJ. Association between cognition and daily life functioning in dementia subtypes. Int J Geriatr Psychiatry 2009;24:764–9.10.1002/gps.2193CrossRef Google Scholar PubMed

Osher, JE, Wicklund, AH, Rademaker, A, Johnson, N, Weintraub, S. The mini-mental state examination in behavioral variant frontotemporal dementia and primary progressive aphasia. Am J Alzheimers Dis Other Demen 2008;22(6):468–73.10.1177/1533317507307173CrossRef Google Scholar

Mioshi, E, Hodges, JR, Hornberger, M. Neural correlates of activities of daily living in frontotemporal dementia. J Geriatr Psychiatry Neurol 2013 Mar;26(1):51–7.CrossRef Google Scholar PubMed

Kaizik, C, O'Connor, C, McKinnon, C, Oyebode, J, Piguet, P, Hodges, J, Mioshi, E. The burden of care in FTD: the under-reported impact on child-carers. Am J Neurodegener Dis 2014;3(Suppl 1):361.Google Scholar

Riedijk, SR, De Vugt, ME, Duivenvoorden, HJ, Niermeijer, MF, van Swieten, JC, Verhey, FRJ, et al. Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord 2006;22:405–12.10.1159/000095750CrossRef Google Scholar PubMed

Mioshi, E, Bristow, M, Cook, R, Hodges, JR. Factors underlying caregiver stress in frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord 2009;27:76–81.10.1159/000193626CrossRef Google Scholar PubMed

Bristow, M, Cook, R, Erzinclioglub, S, Hodges, J. Stress, distress and mucosal immunity in carers of a partner with fronto-temporal dementia. Aging Ment Health 2008;12(5):595–604.10.1080/13607860802343076CrossRef Google Scholar PubMed

Boutoleau-Bretonniere, C, Vercelletto, M, Volteau, C, Renou, P, Lamy, E. Zarit burden inventory and activities of daily living in the behavioral variant of frontotemporal dementia. Dement Geriatr Cogn Disord 2008;25:272–7.10.1159/000117394CrossRef Google Scholar PubMed

Mioshi, E, Foxe, D, Leslie, F, Savage, S, Hsieh, S, Miller, L, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord 2013;27(1):68–73.10.1097/WAD.0b013e318247a0bcCrossRef Google Scholar PubMed

Mioshi, E, McKinnon, C, Savage, S, O'Connor, CM, Hodges, JR. Improving burden and coping skills in frontotemporal dementia caregivers: a pilot study. Alzheimer Dis Assoc Disord 2013;27(1):84–6.10.1097/WAD.0b013e31824a7f5bCrossRef Google Scholar PubMed

Diehl, J, Mayer, T, Forstl, H, Kurz, A. A support group for caregivers of patients with frontotemporal dementia. Dementia 2003;2(2):151–61.10.1177/1471301203002002002CrossRef Google Scholar

Gitlin, LN, Winter, L, Burke, J, Chernett, N, Dennis, MP, Huack, WW. Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study. Am J Geriatr Psychiatry 2008;16(3):229–39.10.1097/01.JGP.0000300629.35408.94CrossRef Google Scholar PubMed

Hall, GR, Shapira, J, Gallagher, M, Denny, SS. Managing differences: care of the person with frontotemporal dementia. J Gerontol Nurs 2013;39(3):10–14.10.3928/00989134-20130131-02CrossRef Google Scholar

Yokota, O, Fujisawa, Y, Takahashi, J, Terada, S, Ishihara, T, Nakashima, H, et al. Effects of group-home care on behavioral symptoms, quality of life, and psychotropic drug use in patients with frontotemporal dementia. J Am Med Dir Assoc 2006;7(5):335–7.10.1016/j.jamda.2006.02.012CrossRef Google Scholar PubMed

Massimo, L, Grossman, M. Patient care and management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2008;23(2):125–31.10.1177/1533317507307961CrossRef Google Scholar PubMed

Bozeat, S, Lambon Ralph, MA, Patterson, K, Hodges, JR. The influence of personal familiarity and context on object use in semantic dementia. Neurocase [Internet] 2002;8(1–2):127–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11997491.Google Scholar PubMed

References

Mendez, MF, Shapira, JS, McMurtray, A, Licht, E, Miller, BL. Accuracy of the clinical evaluation for frontotemporal dementia. Archives of Neurology 2007;64(6):830–5.10.1001/archneur.64.6.830CrossRef Google Scholar PubMed

Chow, TW, Pio, FJ, Rockwood, K. An international needs assessment of caregivers for frontotemporal dementia. The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques 2011;38(5):753–7.Google Scholar PubMed

Rascovsky, K, Hodges, JR, Knopman, D, Mendez, MF, Kramer, JH, Neuhaus, J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: A Journal of Neurology 2011;134(Pt 9):2456–77.10.1093/brain/awr179CrossRef Google Scholar PubMed

Gorno-Tempini, ML, Hillis, AE, Weintraub, S, Kertesz, A, Mendez, M, Cappa, SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006–14.10.1212/WNL.0b013e31821103e6CrossRef Google Scholar PubMed

Mioshi, E, Hsieh, S, Savage, S, Hornberger, M, Hodges, JR. Clinical staging and disease progression in frontotemporal dementia. Neurology 2010;74(20):1591–7.10.1212/WNL.0b013e3181e04070CrossRef Google Scholar PubMed

Woolley, JD, Khan, BK, Murthy, NK, Miller, BL, Rankin, KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. The Journal of Clinical Psychiatry 2011;72(2):126–33.10.4088/JCP.10m06382oliCrossRef Google Scholar PubMed

Wylie, MA, Shnall, A, Onyike, CU, Huey, ED. Management of frontotemporal dementia in mental health and multidisciplinary settings. International Review of Psychiatry 2013;25(2):230–6.10.3109/09540261.2013.776949CrossRef Google Scholar PubMed

Mesulam, MM, Wieneke, C, Thompson, C, Rogalski, E, Weintraub, S. Quantitative classification of primary progressive aphasia at early and mild impairment stages. Brain: A Journal of Neurology 2012;135(Pt 5):1537–53.10.1093/brain/aws080CrossRef Google Scholar PubMed

Diehl-Schmid, J, Schmidt, EM, Nunnemann, S, Riedl, L, Kurz, A, Forstl, H, et al. Caregiver burden and needs in frontotemporal dementia. Journal of Geriatric Psychiatry and Neurology 2013;26(4):221–9.10.1177/0891988713498467CrossRef Google Scholar PubMed

Onyike, CU, Diehl-Schmid, J. The epidemiology of frontotemporal dementia. International Review of Psychiatry 2013;25(2):130–7.Google Scholar PubMed

Hodges, JR, Davies, R, Xuereb, J, Kril, J, Halliday, G. Survival in frontotemporal dementia. Neurology 2003;61(3):349–54.10.1212/01.WNL.0000078928.20107.52CrossRef Google Scholar PubMed

Borroni, B, Grassi, M, Archetti, S, Papetti, A, Del Bo, R, Bonvicini, C, et al. Genetic background predicts poor prognosis in frontotemporal lobar degeneration. Neuro-degenerative Diseases 2011;8(5):289–95.10.1159/000322790CrossRef Google Scholar PubMed

Le Rhun, E, Richard, F, Pasquier, F. Natural history of primary progressive aphasia. Neurology 2005;65(6):887–91.10.1212/01.wnl.0000175982.57472.84CrossRef Google Scholar PubMed

Borroni, B, Benussi, A, Cosseddu, M, Archetti, S, Padovani, A. Cerebrospinal fluid tau levels predict prognosis in non-inherited frontotemporal dementia. Neuro-degenerative Diseases 2014;13(4):224–9.10.1159/000353280CrossRef Google Scholar PubMed

Salmon, E, Perani, D, Collette, F, Feyers, D, Kalbe, E, Holthoff, V, et al. A comparison of unawareness in frontotemporal dementia and Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 2008;79(2):176–9.10.1136/jnnp.2007.122853CrossRef Google Scholar PubMed

The Association for Frontotemporal Degeneration [cited December 2013]. Available from: www.theaftd.org.Google Scholar

Jicha, GA. Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies. Journal of Molecular Neuroscience: MN 2011;45(3):713–23.10.1007/s12031-011-9558-7CrossRef Google Scholar PubMed

Knopman, DS, Kramer, JH, Boeve, BF, Caselli, RJ, Graff-Radford, NR, Mendez, MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain: A Journal of Neurology 2008;131(Pt 11):2957–68.10.1093/brain/awn234CrossRef Google Scholar PubMed

Sapolsky, D, Bakkour, A, Negreira, A, Nalipinski, P, Weintraub, S, Mesulam, MM, et al. Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia. Neurology 2010;75(4):358–66.10.1212/WNL.0b013e3181ea15e8CrossRef Google Scholar PubMed

Dickerson, BC. Quantitating severity and progression in primary progressive aphasia. Journal of Molecular Neuroscience: MN 2011;45(3):618–28.10.1007/s12031-011-9534-2CrossRef Google Scholar PubMed

de Simone, V, Kaplan, L, Patronas, N, Wassermann, EM, Grafman, J. Driving abilities in frontotemporal dementia patients. Dementia and Geriatric Cognitive Disorders 2007;23(1):1–7.10.1159/000096317CrossRef Google Scholar PubMed

Manoochehri, M, Huey, ED. Diagnosis and management of behavioral issues in frontotemporal dementia. Current Neurology and Neuroscience Reports 2012;12(5):528–36.10.1007/s11910-012-0302-7CrossRef Google Scholar PubMed

Huey, ED, Putnam, KT, Grafman, J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006;66(1):17–22.10.1212/01.wnl.0000191304.55196.4dCrossRef Google Scholar PubMed

O'Brien, JT, Burns, A, BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology 2011;25(8):997–1019.10.1177/0269881110387547CrossRef Google Scholar PubMed

Parashos, SA, Wielinski, CL, Giladi, N, Gurevich, T. Falls in Parkinson disease: analysis of a large cross-sectional cohort. Journal of Parkinson's Disease 2013;3(4):515–22.Google Scholar PubMed

Maher, AR, Maglione, M, Bagley, S, Suttorp, M, Hu, JH, Ewing, B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA: The Journal of the American Medical Association 2011;306(12):1359–69.10.1001/jama.2011.1360CrossRef Google Scholar PubMed

Steinberg, M, Lyketsos, CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. The American Journal of Psychiatry 2012;169(9):900–6.10.1176/appi.ajp.2012.12030342CrossRef Google Scholar PubMed

Devanand, DP, Schultz, SK, Sultzer, DL. Discontinuation of risperidone in Alzheimer's disease. The New England Journal of Medicine 2013;368(2):187–8.Google Scholar PubMed

Lopez-Pousa, S, Calvo-Perxas, L, Lejarreta, S, Cullell, M, Melendez, R, Hernandez, E, et al. Use of antidementia drugs in frontotemporal lobar degeneration. American Journal of Alzheimer's Disease and Other Dementias 2012;27(4):260–6.10.1177/1533317512447887CrossRef Google Scholar PubMed

Kerchner, GA, Tartaglia, MC, Boxer, A. Abhorring the vacuum: use of Alzheimer's disease medications in frontotemporal dementia. Expert Review of Neurotherapeutics 2011;11(5):709–17.10.1586/ern.11.6CrossRef Google Scholar PubMed

Boxer, AL, Knopman, DS, Kaufer, DI, Grossman, M, Onyike, C, Graf-Radford, N, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology 2013;12(2):149–56.10.1016/S1474-4422(12)70320-4CrossRef Google Scholar PubMed

Vercelletto, M, Boutoleau-Bretonniere, C, Volteau, C, Puel, M, Auriacombe, S, Sarazin, M, et al. Memantine in behavioral variant frontotemporal dementia: negative results. Journal of Alzheimer's Disease: JAD 2011;23(4):749–59.Google Scholar PubMed

van Balken, I, Litvan, I. Current and future therapeutic approaches in progressive supranuclear palsy. Handbook of Clinical Neurology 2008;89:493–508.10.1016/S0072-9752(07)01246-8CrossRef Google Scholar PubMed

Boeve, BF, Josephs, KA, Drubach, DA. Current and future management of the corticobasal syndrome and corticobasal degeneration. Handbook of Clinical Neurology 2008;89:533–48.10.1016/S0072-9752(07)01249-3CrossRef Google Scholar PubMed

Constantinescu, R, Richard, I, Kurlan, R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Movement Disorders: Official Journal of the Movement Disorder Society 2007;22(15):2141–8; quiz 295.10.1002/mds.21578CrossRef Google Scholar PubMed

Diniz, BS, Machado-Vieira, R, Forlenza, OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatric Disease and Treatment 2013;9:493–500.10.2147/NDT.S33086CrossRef Google Scholar PubMed

ClinicalTrials.gov: A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration [updated June 18, 2010; cited December 12, 2013]. Available from: https://clinicaltrials.gov/show/NCT00703677.Google Scholar

ClinicalTrials.gov: Effects of Tolcapone on Frontotemporal Dementia [updated October 18, 2011; cited December 12, 2013]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00604591.Google Scholar

Finger, EC. New potential therapeutic approaches in frontotemporal dementia: oxytocin, vasopressin, and social cognition. Journal of Molecular Neuroscience: MN 2011;45(3):696–701.10.1007/s12031-011-9550-2CrossRef Google Scholar PubMed

Jesso, S, Morlog, D, Ross, S, Pell, MD, Pasternak, SH, Mitchell, DG, et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain: A Journal of Neurology 2011;134(Pt 9):2493–501.10.1093/brain/awr171CrossRef Google Scholar PubMed

ClinicalTrials.gov: Safety Study of Intranasal Oxytocin in Frontotemporal Dementia [cited May 2012]. Available from: https://clinicaltrials.gov/ct2/show/NCT01386333.Google Scholar

Achi, EY, Rudnicki, SA. ALS and frontotemporal dysfunction: a review. Neurology Research International 2012;2012:806306.10.1155/2012/806306CrossRef Google Scholar PubMed

Buchanan, JA, Christenson, A, Houlihan, D, Ostrom, C. The role of behavior analysis in the rehabilitation of persons with dementia. Behavior Therapy 2011;42(1):9–21.10.1016/j.beth.2010.01.003CrossRef Google Scholar PubMed

Croot, K, Nickels, L, Laurence, F, Manning, M. Impairment- and activity/participation-directed interventions in progressive language impairment: clinical and theoretical issues. Aphasiology 2009;23(2):125–60.10.1080/02687030801943179CrossRef Google Scholar

Taylor, C, Kingma, RM, Croot, K, Nickels, L. Speech pathology services for primary progressive aphasia: exploring an emerging area of practice. Aphasiology 2009;23(2):161–74.10.1080/02687030801943039CrossRef Google Scholar

Khayum, B, Wieneke, C, Rogalski, E, Robinson, J, O'Hara, M. Thinking outside the stroke: treating primary progressive aphasia (PPA). Perspectives on Gerontology 2012;17(2):37–49.10.1044/gero17.2.37CrossRef Google Scholar PubMed

Reich, SG, Grill, SE. Corticobasal degeneration. Current Treatment Options in Neurology 2009;11(3):179–85.10.1007/s11940-009-0021-9CrossRef Google Scholar PubMed

Nunnemann, S, Kurz, A, Leucht, S, Diehl-Schmid, J. Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions. International Psychogeriatrics/IPA 2012;24(9):1368–86.CrossRef Google Scholar PubMed

Denny, SS, Morhardt, D, Gaul, JE, Lester, P, Andersen, G, Higgins, PJ, et al. Caring for children of parents with frontotemporal degeneration: a report of the AFTD Task Force on Families With Children. American Journal of Alzheimer's Disease and Other Dementias 2012;27(8):568–78.10.1177/1533317512459791CrossRef Google Scholar PubMed

Banks, SJ, Weintraub, S. Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia. Journal of Geriatric Psychiatry and Neurology 2008;21(2):133–41.10.1177/0891988708316856CrossRef Google Scholar PubMed

Banks, SJ, Weintraub, S. Generalized and symptom-specific insight in behavioral variant frontotemporal dementia and primary progressive aphasia. The Journal of Neuropsychiatry and Clinical Neurosciences 2009;21(3):299–306.10.1176/jnp.2009.21.3.299CrossRef Google Scholar PubMed

Chancellor, B, Duncan, A, Chatterjee, A. Art therapy for Alzheimer's disease and other dementias. Journal of Alzheimer's Disease: JAD 2014;39(1):1–11.10.3233/JAD-131295CrossRef Google Scholar PubMed

Brodaty, H, Arasaratnam, C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. The American Journal of Psychiatry 2012;169(9):946–53.10.1176/appi.ajp.2012.11101529CrossRef Google Scholar PubMed

Shnall, A, Agate, A, Grinberg, A, Huijbregts, M, Nguyen, MQ, Chow, TW. Development of supportive services for frontotemporal dementias through community engagement. International Review of Psychiatry 2013;25(2):246–52.10.3109/09540261.2013.767780CrossRef Google Scholar PubMed

Riedijk, SR, De Vugt, ME, Duivenvoorden, HJ, Niermeijer, MF, Van Swieten, JC, Verhey, FR, et al. Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2006;22(5–6):405–12.10.1159/000095750CrossRef Google Scholar PubMed

Gitlin, LN, Winter, L, Dennis, MP, Hodgson, N, Hauck, WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. Journal of the American Geriatrics Society 2010;58(8):1465–74.10.1111/j.1532-5415.2010.02971.xCrossRef Google Scholar PubMed

Selwood, A, Johnston, K, Katona, C, Lyketsos, C, Livingston, G. Systematic review of the effect of psychological interventions on family caregivers of people with dementia. Journal of Affective Disorders 2007;101(1–3):75–89.10.1016/j.jad.2006.10.025CrossRef Google Scholar PubMed

Cooper, C, Mukadam, N, Katona, C, Lyketsos, CG, Ames, D, Rabins, P, et al. Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia. International Psychogeriatrics/IPA 2012;24(6):856–70.10.1017/S1041610211002614CrossRef Google Scholar PubMed

Mioshi, E, McKinnon, C, Savage, S, O'Connor, CM, Hodges, JR. Improving burden and coping skills in frontotemporal dementia caregivers : a pilot study. Alzheimer Disease and Associated Disorders 2013;27(1):84–6.CrossRef Google Scholar PubMed

Wong, CC, Wallhagen, MI. Family caregivers of individuals with frontotemporal dementia: examining the relationship between coping and caregiver physical and mental health. Journal of Gerontological Nursing 2014;40(1):30–40.10.3928/00989134-20130827-05CrossRef Google Scholar PubMed

Dowling, GA, Merrilees, J, Mastick, J, Chang, VY, Hubbard, E, Moskowitz, JT. Life enhancing activities for family caregivers of people with frontotemporal dementia. Alzheimer Disease and Associated Disorders 2014;28(2):175–81.10.1097/WAD.0b013e3182a6b905CrossRef Google Scholar PubMed

Chow, TW, Fridhandler, JD, Binns, MA, Lee, A, Merrilees, J, Rosen, HJ, et al. Trajectories of behavioral disturbance in dementia. Journal of Alzheimer's Disease: JAD 2012;31(1):143–9.Google Scholar PubMed

Gallagher, MM, McLean, A, Wilson, R. Discussion of Hospice and End-of-Life Symptoms in FTD. Phoenix, Arizona: Hospice of the Valley, 2011.Google Scholar

Van den Berg, JP, Kalmijn, S, Lindeman, E, Veldink, JH, de Visser, M, Van der Graaff, MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65(8):1264–7.10.1212/01.wnl.0000180717.29273.12CrossRef Google Scholar PubMed

References

Kaye, ED, Petrovic-Poljak, A, Verhoeff, NP, Freedman, M. Frontotemporal dementia and pharmacologic interventions. J Neuropsychiatry Clin Neurosci 2010;22 (1):19–29.CrossRef Google Scholar PubMed

Angoa-Perez, M, Kane, MJ, Briggs, DI, Sykes, CE, Shah, MM, Francescutti, DM, et al. Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity. J Neurochem 2012;121:974–84.10.1111/j.1471-4159.2012.07739.xCrossRef Google Scholar PubMed

Procter, AW, Qurne, M, Francis, PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999;10 Suppl 1:80–4.10.1159/000051219CrossRef Google Scholar PubMed

Franceschi, M, Anchisi, D, Pelati, O, Zuffi, M, Matarrese, M, Moresco, RM, et al. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 2005;57:216–25.10.1002/ana.20365CrossRef Google Scholar PubMed

Yang, Y, Schmitt, HP. Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervations. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol 2001;101:256–70.10.1007/s004010000293CrossRef Google Scholar

Hermann, N, Black, SE, Chow, T, Cappell, J, Tang-Wai, DF, Lanctôt, KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 2012;20:789–97.10.1097/JGP.0b013e31823033f3CrossRef Google Scholar

Swartz, JR, Miller, BL, Lesser, IM, Darby, AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997;58:212–16.10.4088/JCP.v58n0506CrossRef Google Scholar PubMed

Chow, TW, Mendez, MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2002;17:276–72.10.1177/153331750201700504CrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, Cazzato, G, Bava, A. Frontotemporal dementia: paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003;49:13–19.10.1159/000067021CrossRef Google Scholar PubMed

Mendez, MF, Shapira, JS, Miller, BL. Stereotypical movements and frontotemporal dementia. Mov Disord 2005;20:742–5.10.1002/mds.20465CrossRef Google Scholar PubMed

Anneser, JM, Jox, RJ, Borasio, GD. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007;8:189–90.10.1080/17482960601073543CrossRef Google Scholar

Prodan, CI, Monnon, M, Ross, ED. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry 2009;80:1416–17.CrossRef Google Scholar

Ikeda, M, Shigenobu, K, Fukuhara, R, Hokoishi, K, Maki, N, Nebu, A, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004;17:117–21.10.1159/000076343CrossRef Google Scholar PubMed

Furlan, JC, Henri-Bhargava, A, Freedman, M. Clomipramine in the treatment of compulsive behavior in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2014;28:95–8.10.1097/WAD.0b013e318265c104CrossRef Google Scholar PubMed

Deakin, JB, Rahman, S, Nestor, PJ, Hodges, JR, Sahakian, BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharamcology(Berl) 2004;172:400–8.Google Scholar

Lebert, F, Stekke, W, Hasenbroekx, C, Pasquier, F. Frontotemoporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17:355–9.10.1159/000077171CrossRef Google Scholar

Huey, ED, Putnam, KT, Grafman, J. A systematic review of neurotransmitter deficits and treatments. Neurology 2006;66:17–22.10.1212/01.wnl.0000191304.55196.4dCrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, Cattaruzza, T, Cazzato, G, Bava, A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004;21:93–107.10.2165/00002512-200421140-00003CrossRef Google Scholar PubMed

Kertesz, A, Morlog, D, Light, M, Blair, M, Davidson, W, Jesso, S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008;25:178–85.10.1159/000113034CrossRef Google Scholar PubMed

Mendez, MF, Shapira, JS, McMurtray, A, Licht, E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007;15:84–7.CrossRef Google Scholar PubMed

Kimura, T, Takamatsu, J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int 2013;13:506–7.Google Scholar PubMed

Rinne, JO, Laine, M, Kaasinen, V, Norvasuo-Heilä, MK, Någren, K, Helenius, H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002;58:1489–93.10.1212/WNL.58.10.1489CrossRef Google Scholar PubMed

Sperfeld, AD, Collatz, MB, Baier, H, Palmbach, M, Storch, A, Schwarz, J, et al. FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999;46:708–15.10.1002/1531-8249(199911)46:5<708::AID-ANA5>3.0.CO;2-K3.0.CO;2-K>CrossRef Google Scholar PubMed

Kanazawa, I, Kwak, S, Sasaki, H, Muramoto, O, Mizutani, T, Hori, A, et al. Studies on neurotransmitter markers of the basal ganglia in Pick's disease, with special reference to dopamine reduction. J Neurol Sci 1988;83:63–74.10.1016/0022-510X(88)90020-2CrossRef Google Scholar PubMed

Curtis, RC, Resch, DS. Case of Pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol 2000;20:384–5.10.1097/00004714-200006000-00018CrossRef Google Scholar PubMed

Fellgiebel, A, Müller, MJ, Hiemke, C, Bartenstein, P, Schreckenberger, M. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 2007;8:123–6.10.1080/15622970601016538CrossRef Google Scholar

Reeves, RR, Perry, CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol 2013;33:145–6.10.1097/01.jcp.0000426190.64916.3bCrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, Cazzato, G, Griggio, S, Bava, A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003;18:205–14.10.1177/153331750301800410CrossRef Google Scholar PubMed

Huey, ED, Garcia, C, Wassermann, EM, Tierney, MC, Grafman, J. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry 2008;69:1981–2.10.4088/JCP.v69n1219aCrossRef Google Scholar PubMed

Pijnenburg, YA, Sampson, EL, Harvey, RJ, Fox, NC, Rossor, MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry 2003;18:67–72.10.1002/gps.774CrossRef Google Scholar PubMed

Moretti, R, Torre, P, Antonello, RM, Cazzato, G, Bava, A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry 2002;17:391–2.10.1002/gps.602CrossRef Google Scholar PubMed

Rahman, S, Robbins, TW, Hodges, JR, Mehta, MA, Nestor, PJ, Clark, L, et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006;31:651–8.10.1038/sj.npp.1300886CrossRef Google Scholar PubMed

Reed, DA, Johnson, NA, Thompson, C, Weintraub, S, Mesulam, MM. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann Neurol 2004;56:750.10.1002/ana.20301CrossRef Google Scholar PubMed

Poetter, CE, Stewart, JT. Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. J Clin Psychopharmacol 2012;31:137–8.Google Scholar

Cruz, M, Marinho, V, Fontenelle, LF, Engelhardt, E, Laks, J. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol 2008;21:104–6.10.1097/WNN.0b013e31816bdf73CrossRef Google Scholar

Nestor, PJ. Reversal of abnormal eating and drinking behavior in a frontotemporal lobar degeneration patient using low-dose topiramate. J Neurol Neurosurg Psychiatry 2012;83:349–50.10.1136/jnnp.2010.238899CrossRef Google Scholar

Singam, C, Walterfang, M, Mocellin, R, Evans, A, Velakoulis, D. Topiramate for abnormal eating behavior in frontotemporal dementia. Behav Neurol 2013;27:285–6.10.1155/2013/547853CrossRef Google Scholar PubMed

Shinagawa, S, Tsuno, N, Nakayama, K. Managing abnormal eating behaviors in frontotemporal lobar degeneration in patients with topiramate. Psychogeriatrics 2013;13:58–61.10.1111/j.1479-8301.2012.00429.xCrossRef Google Scholar PubMed

Reisberg, B, Doody, R, Stöffler, A, Schmitt, F, Ferris, S, Möbius, HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333–41.10.1056/NEJMoa013128CrossRef Google Scholar PubMed

Tariot, PN, Farlow, MR, Grossberg, GT, Graham, SM, McDonald, S, Geergel, I, et al. Memantine treatment in patients with moderate to severe Alzheimer Disease already receiving donepezil. JAMA 2004;291:317–24.10.1001/jama.291.3.317CrossRef Google Scholar PubMed

Diehl-Schmid, J, Förstl, H, Perneczky, R, Pohl, C, Kurz, A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 2008;23:754–9.CrossRef Google Scholar PubMed

Cummings, JL, Schneider, E, Tariot, PN, Graham, SM; Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil. Neurology 2006;67:57–63.10.1212/01.wnl.0000223333.42368.f1CrossRef Google Scholar PubMed

Swanberg, MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2007;21:164–6.10.1097/WAD.0b013e318047df5dCrossRef Google Scholar PubMed

Boxer, AL, Lipton, AM, Womack, K, Merrilees, J, Neuhaus, J, Pavlic, D, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2009;23:211–17.10.1097/WAD.0b013e318197852fCrossRef Google Scholar PubMed

Vercelletto, M, Boutoleau-Bretonnière, C, Volteau, C, Puel, M, Auriacombe, S, Sarazin, M, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimer Dis 2011;23:749–59.CrossRef Google Scholar PubMed

Boxer, AL, Knopman, DS, Kaufer, DI, Grossman, M, Onyike, C, Graf-Radford, N, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol 2013;12:149–56.10.1016/S1474-4422(12)70320-4CrossRef Google Scholar

Khlistunova, I, Biernat, J, Wang, Y, Pickhardt, M, von Bergen, M, Gazova, Z, et al. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006;281:1205–14.10.1074/jbc.M507753200CrossRef Google Scholar PubMed

Van der Jeugd, A, Hochgräfe, K, Ahmed, T, Decker, JM, Sydow, A, Hofmann, A, et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human tau. Acta Neuropathol 2012;123:787–805.10.1007/s00401-012-0987-3CrossRef Google Scholar PubMed

Bramblett, GT, Goedert, M, Jakes, R, Merrick, SE, Trojanowski, JQ, Lee, VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993;10: 1089–99.10.1016/0896-6273(93)90057-XCrossRef Google Scholar PubMed

Hampel, H, Ewers, M, Bürger, K, Annas, P, Mörtberg, A, Bogstedt, A, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70: 922–31.10.4088/JCP.08m04606CrossRef Google Scholar PubMed

Tolosa, E, Litvan, I, Höglinger, GU, Burn, D, Lees, A, Andrés, MV, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 2014;29:470–8. Feb 14. doi: 10.1002/mds.25824. [Epub ahead of print]CrossRef Google Scholar PubMed

Zeltia [internet] [place unknown][publisher unknown] [Oct 2012] Available from http://www.zeltia.es/media/docs/esflsziq.pdf?ie=UTF-8&oe=UTF8&q=prettyphoto&iframe=true&width=100%&height=100%Google Scholar

Min, SW, Cho, SH, Zhou, Y, Schroeder, S, Haroutunian, V, Seeley, WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010;67:853–66.10.1016/j.neuron.2010.08.044CrossRef Google Scholar PubMed

Boxer, AL, Gold, M, Huey, E, Gao, FB, Burton, EA, Chow, T, et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement 2013;9:176–88.Google Scholar PubMed

Boimel, M, Grigoriadis, N, Lourbopoulos, A, Haber, E, Abramsky, O, Rosenmann, H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472–85.10.1016/j.expneurol.2010.05.010CrossRef Google Scholar PubMed

Asuni, AA, Boutajangout, A, Quartermain, D, Sigurdsson, EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115–29.10.1523/JNEUROSCI.2361-07.2007CrossRef Google Scholar

Boutajangout, A, Quartermain, D, Sigurdsson, EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30:16559–66.10.1523/JNEUROSCI.4363-10.2010CrossRef Google Scholar

Fierce Biotech [internet][place unknown][publisher unknown][Jan 2014] Available from http://www.fiercevaccines.com/story/ac-immune-begins-first-trial-tau-targeting-alzheimers-vaccine/2014-01-13 Google Scholar

Boutajangout, A, Ingadottir, J, Davies, P, Sigurdsson, EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118:658–67.10.1111/j.1471-4159.2011.07337.xCrossRef Google Scholar

Chai, X, Wu, S, Murray, TK, Kinley, R, Cella, CV, Sims, H, et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem 2011;286:34457–67.10.1074/jbc.M111.229633CrossRef Google Scholar PubMed

Yanamandra, K, Kfoury, N, Jiang, H, Mahan, TE, Ma, S, Maloney, SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013;80:402–14.10.1016/j.neuron.2013.07.046CrossRef Google Scholar PubMed

Higuchi, M, Lee, VM, Trojanowski, JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002;2:131–50.CrossRef Google Scholar PubMed

Erez, H, Shemesh, OA, Spira, ME. Rescue of tau-induced synaptic transmission pathology by paclitaxel. Front Cell Neurosci 2014;8:34. doi: 10.3389/fncel.2014.00034CrossRef Google Scholar PubMed

Brunden, KR, Ballatore, C, Lee, VM, Smith, AB 3rd, Trojanowski, JQ. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 2012;40:661–6.10.1042/BST20120010CrossRef Google Scholar PubMed

Barten, DM, Fanara, P, Andorfer, C, Hoque, N, Wong, PY, Husted, KH, et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 2012;32:7137–45.10.1523/JNEUROSCI.0188-12.2012CrossRef Google Scholar PubMed

ClinicalTrials.gov [internet][place unknown][NIH][Oct 2013] http://clinicaltrials.gov/ct2/show/NCT01966666?term-tpi+287&rank Google Scholar

MacKenzie, IR, Neumann, M, Bigio, EH, Cairns, NJ, Alafuzoff, I, Kril, J, et al. Nomenclature for neuropathological subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117:15–18.10.1007/s00401-008-0460-5CrossRef Google Scholar PubMed

Sephton, CF, Cenik, B, Cenik, BK, Herz, J, Yu, G. TDP-43 in central nervous system development and function: clues to TDP-43 associated neurodegeneration. Biol Chem 2012;393:589–94.CrossRef Google Scholar PubMed

Arnold, ES, Ling, SC, Huelga, SC, Lagier-Tourenne, C, Polymenidou, M, Ditsworth, D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci USA 2013;110:E736–45.10.1073/pnas.1222809110CrossRef Google Scholar PubMed

Janssens, J, Wils, H, Kleinberger, G, Joris, G, Cuijt, I, Ceuterick-de Groote, C, et al. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol 2013;48:22–35.10.1007/s12035-013-8427-5CrossRef Google Scholar PubMed

Huang, C, Tong, J, Bi, F, Zhou, H, Xia, XG. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J. Clin Invest 2012;122:107–18.10.1172/JCI59130CrossRef Google Scholar PubMed

Hu, WT, Watts, K, Grossman, M, Glass, J, Lah, JJ, Hales, C, et al. Reduced CSF p-tau181 to tau ratio is a biomarker for FTLD-TDP. Neurology 2013;81:1945–52.10.1212/01.wnl.0000436625.63650.27CrossRef Google Scholar PubMed

Maruyama, M, Shimada, H, Suhara, T, Shinotoh, H, Ji, B, Maeda, J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79(6):1094–108.10.1016/j.neuron.2013.07.037CrossRef Google Scholar

van Swieten, JC, Heutink, P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7:965–74.CrossRef Google Scholar PubMed

Finch, N, Baker, M, Crook, R, Swanson, K, Kuntz, K, Surtees, R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009;132:583–91.10.1093/brain/awn352CrossRef Google Scholar PubMed

Ghidoni, R, Benussi, L, Glionna, M, Franzoni, M, Binetti, G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008;71:1235–39.CrossRef Google Scholar PubMed

Sleegers, K, Brouwers, N, Van Damme, P, Engelborghs, S, Gijselinck, I, van der Zee, J, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 2009;65:603–9.10.1002/ana.21621CrossRef Google Scholar PubMed

Rademakers, R, Eriksen, JL, Baker, M, Robinson, T, Ahmed, Z, Lincoln, SJ, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 2008;17:3631–42.10.1093/hmg/ddn257CrossRef Google Scholar

Tang, W, Lu, Y, Tian, QY, Zhang, Y, Guo, FJ, Liu, GY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011;332:478–84.CrossRef Google Scholar

Miller, ZA, Rankin, KP, Graff-Radford, NR, Takada, LT, Sturm, VE, Cleveland, CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry 2013;84:956–62.10.1136/jnnp-2012-304644CrossRef Google Scholar PubMed

Thurner, L, Preuss, KD, Fadle, N, Regitz, E, Klemm, P, Zaks, M, et al. Progranulin antibodies in autoimmune disease. J Autoimmun 2013;42:29–38.10.1016/j.jaut.2012.10.003CrossRef Google Scholar

Cenik, B, Sephton, CF, Dewey, CM, Xian, X, Wei, S, Yu, K, et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem 2011;286:16101–8.10.1074/jbc.M110.193433CrossRef Google Scholar PubMed

Lee, WC, Almeida, S, Prudencio, M, Caulfield, TR, Zhang, YJ, Bauer, PO, et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum Mol Genet 2014;23(6):1467–78. doi: 10.1093/hmg/ddt534. [Epub 2013]CrossRef Google Scholar PubMed

Capell, A, Liebscher, S, Fellerer, K, Brouwers, N, Willem, M, Lammich, S, et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 2011;31:1885–94.10.1523/JNEUROSCI.5757-10.2011CrossRef Google Scholar PubMed

Alberici, A, Archetti, S, Pilotto, A, Premi, E, Cosseddu, M, Bianchetti, A, et al. Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation. Neurol Sci 2014;35(8):1215–19.10.1007/s10072-014-1683-yCrossRef Google Scholar PubMed

ClinicalTrials.gov [internet][place unknown][NIH][Mar 2013] http://clinicaltrials.gov/ct2/show/NCT01835665?term=progranulin+nimodipine&rank=1 Google Scholar

Sjögren, M, Folkesson, S, Blennow, K, Tarkowski, E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry 2004;75:1574–6.10.1136/jnnp.2003.019422CrossRef Google Scholar PubMed

Perry, DC, Lehmann, M, Yokoyama, JS, Karydas, A, Lee, JJ, Coppola, G, et al. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 2013;70:77477–8.10.1001/2013.jamaneurol.393CrossRef Google Scholar PubMed

Sha, SJ, Boxer, A. Treatment implications of C9ORF72. Alzheimers Res Ther 2012;4:46.10.1186/alzrt149CrossRef Google Scholar PubMed

Boxer, AL, Mackenzie, IR, Boeve, BF, Baker, M, Seeley, WW, Crook, R, et al. Clinical, neuroimaging and neuropatholgoical features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry 2011;82:196–203.10.1136/jnnp.2009.204081CrossRef Google Scholar

DeJesus-Hernandez, M, Mackenzie, IR, Boeve, BF, Boxer, AL, Baker, M, Rutherford, NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245–56.10.1016/j.neuron.2011.09.011CrossRef Google Scholar PubMed

Renton, AE, Majounie, E, Waite, A, Simón-Sánchez, J, Rollinson, S, Gibbs, JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257–68.CrossRef Google Scholar

Al-Sarraj, S, King, A, Troakes, C, Smith, B, Maekawa, S, Bodi, I, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 2011;122:691–702.10.1007/s00401-011-0911-2CrossRef Google Scholar PubMed

Levine, TP, Daniels, RD, Gatta, AT, Wong, LH, Hayes, MJ. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013;29:499–503.10.1093/bioinformatics/bts725CrossRef Google Scholar PubMed

Ashe, PE, Bieniek, KF, Gendron, TF, Caulfield, T, Lin, WL, DeJesus-Hernandez, M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013;77 (4):639–46.Google Scholar

Miller, T, Pestronk, A, David, W, Rothstein, J, Simpson, E, Appel, SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomized, first-in-man study. Lancet Neurol 2013;12:435–42.10.1016/S1474-4422(13)70061-9CrossRef Google Scholar PubMed

Donnelly, CJ, Zhang, PW, Pham, JT, Heusler, AR, Mistry, NA, Vidensky, S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80:415–28.10.1016/j.neuron.2013.10.015CrossRef Google Scholar PubMed

Lagier-Tourenne, C, Baughn, M, Rigo, F, Sun, S, Liu, P, Li, HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA 2013;110:E4530–9.10.1073/pnas.1318835110CrossRef Google Scholar PubMed

Flannick, J, Thorleifsson, G, Beer, NL, Jacobs, SB, Grarup, N, Burtt, NP, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 2014;46(4):357–63. doi: 10.1038/ng.2915.CrossRef Google Scholar PubMed

Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–72.10.1016/j.cell.2007.11.019CrossRef Google Scholar PubMed

Almeida, S, Gascon, E, Tran, H, Chou, HJ, Gendron, TF, Degroot, S, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC derived-human neurons. Acta Neuropathol 2013;126:385–99.10.1007/s00401-013-1149-yCrossRef Google Scholar PubMed

Almeida, S, Zhang, Z, Coppola, G, Mao, W, Futai, K, Karydas, A, et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep 2012;2:789–98.10.1016/j.celrep.2012.09.007CrossRef Google Scholar PubMed

Fong, H, Wang, C, Knoferle, J, Walker, D, Balestra, ME, Tong, LM, et al. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports 2013;1:226–34.10.1016/j.stemcr.2013.08.001CrossRef Google Scholar PubMed

Alzforum [internet][publisher unknown][date unknown] Available from http://www.alzforum.org/research-models Google Scholar

Santacruz, K, Lewis, J, Spires, T, Paulson, J, Kotilinek, L, Ingelsson, M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005;309:476–81.10.1126/science.1113694CrossRef Google Scholar

Tsai, KJ, Yang, CH, Fang, YH, Cho, KH, Chien, WL, Wang, WT, et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med 2010;207:1661–73.10.1084/jem.20092164CrossRef Google Scholar PubMed

Yin, F, Dumont, M, Banerjee, R, Ma, Y, Li, H, Lin, MT, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J 2010;24:4639–47.Google Scholar PubMed

Filiano, AJ, Martens, LH, Young, AH, Warmus, BA, Zhou, P, Diaz-Ramirez, G, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci 2013;33:5352–61.10.1523/JNEUROSCI.6103-11.2013CrossRef Google Scholar PubMed

Bhaskar, K, Konerth, M, Kokiko-Cochran, ON, Cardona, A, Ransohoff, RM, Lamb, BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010;68:19–31.10.1016/j.neuron.2010.08.023CrossRef Google Scholar PubMed

Schneider, JA, Arvanitakis, Z, Bang, W, Bennett, DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–204.10.1212/01.wnl.0000271090.28148.24CrossRef Google Scholar PubMed

Scherling, CS, Hall, T, Berisha, F, Klepac, K, Karydas, A, Coppola, G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116–26.10.1002/ana.24052CrossRef Google Scholar PubMed

Landqvist Waldö, M, Frizell Santillo, A, Passant, U, Zetterberg, H, Rosengren, L, Nilsson, C, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 2013;13:54.10.1186/1471-2377-13-54CrossRef Google Scholar PubMed

Whitwell, JL, Weigand, SD, Gunter, JL, Boeve, BF, Rademakers, R, Baker, M, et al. Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. Neurology 2011;77:393–8.10.1212/WNL.0b013e318227047fCrossRef Google Scholar PubMed

Bateman, RJ, Xiong, C, Benzinger, TL, Fagan, AM, Goate, A, Fox, NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.10.1056/NEJMoa1202753CrossRef Google Scholar PubMed

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Book contents

Section 5 - Treatment

Information

Access options

Book purchase

Temporarily unavailable

References

References

References

References

Accessibility standard: Unknown

Save book to Kindle

Save book to Dropbox

Save book to Google Drive